Notícias e Atividades da Strand Therapeutics

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Strand Therapeutics

• Jake Becraft, Chief Executive Officer and Director
• Jory Bell, Director
• Ala Alenazi, Director

Recentes movimentos de executivos em Strand Therapeutics

• Kunal Bhatia, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 30 de abril de 2026).
• Jeb Keiper, ingressou na Companhia como Independent Director  (Notícia publicada em 3 de dezembro de 2025).
• Prashant Nambiar antes Senior Vice President of Discovery and Translational Development, foi promovido a Chief Scientific Officer  (Notícia publicada em 5 de novembro de 2025).

Clique aqui para ver outras movimentos em Strand Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Strand Therapeutics.

Strand Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Strand Therapeutics

• Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer
• Phase 1 dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors - Strand Therapeutics
• STX-003: Cancer Immunotherapy with systemic delivery of mRNA utilizing programmable genetic circuits for precise regulation of IL-12 expression and reduced toxicity - Strand Therapeutics
• Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
• STX-003: Utilizing Programmable Genetic Circuits for Tumor-Specific IL-12 Expression and Reduced Toxicity with Systemically Delivered mRNA - Strand Therapeutics
• STX-003: A Novel Systemically-Delivered mRNA-Based Cancer Therapy Utilizing a Programmable Genetic Circuit Platform for Tumor-Specific Protein Expression and Reduced Toxicity - Strand Therapeutics
• Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors
• Unlocking mRNA’s cancer-fighting potential
• Strand Therapeutics Receives IND Clearance for Programmable mRNA Therapy STX-001 to Treat Solid Tumors
• Delivering on the Promise of Personalized mRNA Therapeutics
• View more press releases Close

Redes sociais sobre Strand Therapeutics

• Strand Therapeutics na Wikipedia, Google News e Yahoo Finance
• Strand Therapeutics na LinkedIn, X (Twitter) e YouTube